Non-tuberculous Mycobacterial (NTM) Infections Market Expected to Witness Significant Growth Through 2036, Driven by Rising Disease Burden and Emerging Targeted Therapies | DelveInsight

The Non-tuberculous Mycobacterial (NTM) Infections market is anticipated to witness substantial growth across the seven major markets (7MM) during the forecast period (2022-2036), driven by increasing disease prevalence, improved diagnostic capabilities, greater clinical awareness, and the development of innovative therapies targeting difficult-to-treat NTM infections. With pipeline candidates such as Epetraborole and NUZYRA (omadacycline) advancing through clinical development, the treatment landscape is expected to evolve significantly over the coming decade.

DelveInsight's "Non-tuberculous Mycobacterial (NTM) Infections Market Insight, Epidemiology, and Market Forecast-2036" provides a comprehensive assessment of disease epidemiology, current treatment practices, marketed therapies, emerging pipeline assets, patient burden, pricing and reimbursement, market dynamics, and commercial opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The report further evaluates historical and forecasted market trends, competitive intelligence, drug uptake projections, market access scenarios, key opinion leader perspectives, and unmet clinical needs influencing the future NTM infections treatment landscape. It offers valuable strategic insights for pharmaceutical companies, healthcare providers, investors, and other stakeholders operating in the infectious disease space.

To know in detail about the Non-tuberculous Mycobacterial (NTM) Infections market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here;
https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Non-tuberculous Mycobacterial (NTM) Infections Market Report

• The NTM infections market is expected to expand steadily through 2036, supported by increasing diagnosed cases, advances in diagnostic technologies, and the anticipated launch of emerging targeted therapies.
• Non-tuberculous mycobacterial (NTM) lung disease is caused by mycobacteria other than Mycobacterium tuberculosis and primarily affects individuals with underlying lung disorders or compromised immune systems. Common symptoms include chronic cough, fatigue, and shortness of breath, often requiring prolonged multidrug antibiotic therapy.
• ARIKAYCE (amikacin liposome inhalation suspension) is currently the only FDA-approved therapy specifically indicated for the treatment of NTM infections in adults with treatment-refractory Mycobacterium avium complex (MAC) lung disease.
• The treatment landscape is evolving with promising investigational therapies including Epetraborole and NUZYRA (omadacycline), which are expected to address major unmet needs associated with resistant and difficult-to-treat NTM infections.
• In February 2026, Insmed announced plans to submit a supplemental New Drug Application (sNDA) to the US FDA for ARIKAYCE, pending positive ENCORE trial results, to expand its indication to all patients with MAC lung disease.
• The report forecasts continued growth of the 7MM NTM infections market, driven by increasing disease burden, improved diagnosis, and expanding therapeutic options.

Key Factors Driving the Non-tuberculous Mycobacterial (NTM) Infections Market

Increasing Disease Awareness and Diagnosis: Improvements in microbiological testing, molecular diagnostics, and physician awareness are enabling earlier identification of NTM infections, reducing underdiagnosis caused by overlapping clinical and radiological features with other pulmonary diseases.

Advancement of Novel Therapies: The clinical development of therapies such as Epetraborole and NUZYRA (omadacycline) is expected to expand treatment options beyond conventional multidrug antibiotic regimens and address persistent unmet medical needs.

Growing Burden of Chronic Lung Diseases: Rising prevalence of chronic respiratory conditions such as bronchiectasis, COPD, and other underlying pulmonary disorders continues to increase the population at risk for NTM infections.

Regulatory and Clinical Progress: Continued regulatory support, orphan drug designations, and ongoing clinical development programs are accelerating innovation and strengthening the future therapeutic landscape for NTM infections.

Non-tuberculous Mycobacterial (NTM) Infections Market Analysis

Treatment of NTM infections requires individualized, species-specific multidrug regimens that often continue for months or years. Current management commonly includes macrolides (azithromycin or clarithromycin), ethambutol, rifamycins, fluoroquinolones, intravenous antibiotics, and supportive therapies such as airway clearance techniques, pulmonary rehabilitation, and nutritional support. While ARIKAYCE has significantly advanced treatment for refractory MAC lung disease, substantial unmet needs remain due to prolonged treatment duration, antimicrobial resistance, tolerability concerns, and limited therapeutic options for infections caused by Mycobacterium abscessus. The anticipated introduction of novel therapies, coupled with rising disease awareness and improved diagnostic capabilities, is expected to drive sustained market growth throughout the forecast period.

Get a Free sample for the Non-tuberculous Mycobacterial (NTM) Infections Market Forecast, Size & Share Analysis Report: Non-tuberculous Mycobacterial (NTM) Infections Market Forecast

Non-tuberculous Mycobacterial (NTM) Infections Competitive Landscape

The Non-tuberculous Mycobacterial (NTM) Infections treatment landscape is steadily evolving as increasing disease awareness, improved diagnostics, and advances in antimicrobial drug development drive innovation. Current treatment relies primarily on prolonged multidrug antibiotic regimens tailored to the infecting NTM species, but therapeutic challenges remain due to drug resistance, lengthy treatment duration, poor tolerability, and limited treatment options for refractory infections. The emergence of targeted therapies is expected to significantly improve treatment outcomes during the forecast period.
Currently, ARIKAYCE (amikacin liposome inhalation suspension) remains the only FDA-approved therapy specifically indicated for NTM lung disease caused by Mycobacterium avium complex (MAC) in adults with limited or no alternative treatment options. In parallel, companies including AN2 Therapeutics and Paratek Pharmaceuticals are advancing promising pipeline candidates such as Epetraborole and NUZYRA (omadacycline) to address major unmet clinical needs, particularly in Mycobacterium abscessus infections.

ARIKAYCE (amikacin liposome inhalation suspension): Insmed
ARIKAYCE is the first and only FDA-approved inhaled therapy indicated for the treatment of refractory MAC lung disease as part of a combination antibacterial regimen in adult patients with limited treatment options. The liposomal inhalation formulation enables targeted pulmonary drug delivery while reducing systemic toxicity traditionally associated with intravenous amikacin. The therapy received accelerated FDA approval in September 2018, followed by European Commission marketing authorization in October 2020. Pending positive ENCORE trial results, Insmed plans regulatory submissions in both the United States and Japan to expand its indication.

Epetraborole: AN2 Therapeutics
Epetraborole is an orally available, boron-containing small molecule inhibitor of bacterial leucyl-tRNA synthetase. Although the EBO-301 study in treatment-refractory MAC lung disease did not demonstrate sufficient efficacy, development has shifted toward Mycobacterium abscessus lung disease, where the therapy is currently undergoing Phase II clinical evaluation. In January 2026, the US FDA cleared an investigator-initiated trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole in patients with M. abscessus infections.

NUZYRA (omadacycline): Paratek Pharmaceuticals
NUZYRA is a novel aminomethylcycline antibiotic being developed for NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc). The therapy is currently in Phase IIb clinical development and previously received both Orphan Drug Designation and Fast Track
Designation from the US FDA for infections caused by MAC and MAB. Clinical updates continue to support its development as a potential treatment option for difficult-to-manage NTM infections.

Discover more about therapies set to grab major Non-tuberculous Mycobacterial (NTM) Infections market share @ Non-tuberculous Mycobacterial (NTM) Infections Treatment Landscape

Recent Developments in the Non-tuberculous Mycobacterial (NTM) Infections Treatment Landscape

• In February 2026, Insmed announced that, pending positive topline ENCORE trial results, it plans to submit a supplemental New Drug Application (sNDA) to the US FDA for ARIKAYCE in all patients with MAC lung disease during the second half of 2026 and discuss label expansion with Japan's PMDA.
• In January 2026, AN2 Therapeutics announced that the US FDA cleared OHSU's IND application to initiate an investigator-initiated clinical trial evaluating Epetraborole in patients with Mycobacterium abscessus infections.
• In October 2025, Paratek Pharmaceuticals presented new clinical findings from studies evaluating NUZYRA (omadacycline) at IDWeek 2025.
• In November 2024, Paratek Pharmaceuticals announced positive top-line results from its Phase IIb clinical study evaluating oral NUZYRA in adults with NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc).
• In October 2020, the European Commission granted marketing authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the treatment of MAC lung infections in adults with limited treatment options.
• In September 2018, the US FDA granted accelerated approval to ARIKAYCE for the treatment of refractory MAC lung disease as part of combination antibacterial therapy.

What are Non-tuberculous Mycobacterial (NTM) Infections?

Non-tuberculous Mycobacterial (NTM) infections are caused by mycobacteria other than Mycobacterium tuberculosis and commonly affect individuals with chronic lung disease or weakened immune systems. The disease most frequently manifests as pulmonary NTM infection, although extrapulmonary disease can also occur. Patients typically present with chronic cough, fatigue, weight loss, sputum production, fever, and shortness of breath. Treatment requires prolonged multidrug antibiotic therapy tailored to the infecting species, including Mycobacterium avium complex (MAC), Mycobacterium abscessus complex (MABC), and Mycobacterium kansasii. Due to significant species-specific differences in antimicrobial susceptibility, individualized treatment strategies and long-term monitoring are essential for successful disease management.

Non-tuberculous Mycobacterial (NTM) Infections Epidemiology Segmentation

The report provides detailed epidemiological analysis across the 7MM for the study period 2022-2036, segmented into:

• Total Prevalent Cases of NTM Infections
• Total Diagnosed Prevalent Cases of NTM Infections
• Gender-specific Diagnosed Prevalent Cases of NTM Infections
• Species-specific Diagnosed Prevalent Cases of NTM Infections
• Severity-specific Diagnosed Prevalent Cases of NTM Infections
• Type-specific Diagnosed Prevalent Cases of NTM Infections
• Total Treatable Cases of NTM Infections
• Epidemiology in the United States
• Epidemiology in EU4 and the United Kingdom
• Epidemiology in Japan

Download the report to understand which factors are driving Non-tuberculous Mycobacterial (NTM) Infections epidemiology trends @ Non-tuberculous Mycobacterial (NTM) Infections Epidemiology Forecast

Scope of the Non-tuberculous Mycobacterial (NTM) Infections Market Report

• Study Period: 2022-2036
• Coverage: 7MM (United States, EU4 [Germany, France, Italy, Spain], the United Kingdom, and Japan)
• Key Companies: Insmed, AN2 Therapeutics, Paratek Pharmaceuticals, Tarn Biosciences, and others
• Key Therapies: ARIKAYCE (amikacin liposome inhalation suspension), Epetraborole, NUZYRA (omadacycline), and other emerging therapies
• Market Dynamics: Drivers and Barriers
• Competitive Intelligence: SWOT Analysis, Conjoint Analysis, Pricing Trends, Market Forecast, and Market Access & Reimbursement
• Patient Journey, KOL Views, Emerging Therapy Assessment, and Epidemiology Analysis

To know more about Non-tuberculous Mycobacterial (NTM) Infections companies working in the treatment market, visit @ Non-tuberculous Mycobacterial (NTM) Infections Clinical Trials and Therapeutic Assessment

Table of Contents

• NTM Infections Market Report Introduction
• NTM Infections Market Executive Summary
• NTM Infections Market Overview
• NTM Infections Epidemiology Analysis
• NTM Infections Market Methodology
• NTM Infections Disease Background and Overview
• NTM Infections Signs and Symptoms
• NTM Infections Causes
• NTM Infections Diagnosis
• NTM Infections Treatment Guidelines and Management
• NTM Infections Epidemiology and Patient Population
• NTM Infections Patient Journey
• NTM Infections Marketed Therapies
• NTM Infections Emerging Therapies
• NTM Infections Market Analysis
• NTM Infections Market Forecast (2022-2036)
• NTM Infections Conjoint Analysis
• NTM Infections Pricing and Market Access Analysis
• NTM Infections Reimbursement Scenario
• NTM Infections Key Companies
• NTM Infections Key Products
• NTM Infections Competitive Landscape
• NTM Infections SWOT Analysis
• NTM Infections Unmet Needs
• NTM Infections KOL Views
• NTM Infections Market Drivers and Barriers
• Future Perspectives and Conclusion
• Analyst Views
• Appendix
• About DelveInsight

Media Contact
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.